Exact Sciences Announces Strong Q1 2025 Results and Raises Guidance

Details

The company's Screening revenue was $540 million, up 14%, while Precision Oncology revenue was $167 million, an increase of 2%. Exact Sciences also raised its full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively. In addition, the company launched the Cologuard Plus test, its next-generation colon cancer screening test, and the Oncodetect test, its molecular residual disease and recurrence monitoring test. The company expects to obtain Medicare reimbursement for the Oncodetect test in the second quarter of 2025.

Items reported

Exhibits (1)

About Exact Sciences Corp

Exact Sciences Corp is a prominent biomedical and biotechnology company dedicated to the development, manufacturing, and marketing of proprietary diagnostic tests. Headquartered in Madison, Wisconsin, the company is renowned for its innovative work in the early detection and prevention of colorectal cancer, primarily through its flagship product, Cologuard. This non-invasive stool-based DNA screening test is a breakthrough in cancer diagnostics, allowing for easier and earlier detection of cancerous and pre-cancerous conditions without the need for traditional invasive procedures. Exact Sciences plays a vital role in the health care and life sciences sectors, significantly impacting patient care by providing more accessible screening options. Their commitment to research and development is evident through ongoing efforts to expand their diagnostic offerings, which include tests for other critical health conditions. In the financial markets, Exact Sciences is a key player in the medical diagnostics and biotechnology industries, with substantial influence on the development of new cancer screening methodologies. The company's innovative approach not only aims to improve patient outcomes but also helps reduce costs in healthcare by enabling timely interventions.